30%
Sector coverage target for healthcare and life sciences, measured across every strategy
Rubix Capital is a family office with healthcare and life sciences at the centre of its mandate — a 30% sector coverage target running across every strategy in an endowment-model framework built for generational horizons and underwritten with fiduciary discipline.
Healthcare exposure is expressed through whichever structure fits the opportunity — buyout, credit, venture, or real assets. What stays constant is the vertical lens and the standard of evidence applied to it.
Novel modalities and platforms, underwritten on mechanism of action and clinical endpoint — not narrative.
Diagnostics, surgical, and monitoring technologies with defensible engineering and a clear regulatory path.
Software, data, and machine learning that extend the reach of clinical care rather than obscure it.
Delivery, infrastructure, and services meeting rising demand across Asia-Pacific and the Middle East.
Most allocators evaluate a healthcare manager on IRR and MOIC. That is necessary and insufficient. The questions that determine outcomes are clinical: does the mechanism make sense, is the endpoint meaningful, is the regulatory strategy viable, and is the patient population real.
Rubix underwrites healthcare with a lens drawn from medicine — a family lineage at the forefront of clinical practice for more than thirty years, applied to the discipline of capital allocation.
That lens does not stay in one bucket. The habits of clinical diligence — insisting on the evidence, distrusting the compelling story, weighting the base rate — travel to every other strategy in the book.
Defence comes before offence. Most of the work goes into the reasons not to commit: the key-person exposure, the fee waterfall that does not survive scrutiny, the track record a public-market equivalent quietly dismantles. Strategic bands are sacred; tactical tilts operate within them, never through them.
Strategy weights describe how capital is structured. Sector coverage describes what it is exposed to. Both are governed by bands; neither is a prediction.
Beneath the framework sits Synapse, a proprietary intelligence overlay. It does not allocate to asset classes; it reads the structural conditions under which returns are made — reconciling manager claims against primary filings, positioning each opportunity on its cycle, and testing it against historical analogues at a scale no committee calendar can reach.
Strategic bands remain sacred. Synapse informs positioning within them — never through them. The model, its dimensions, and its gates are proprietary and not disclosed.
Figures are illustrative of the strategic framework and subject to change. They are not a recommendation, an offer, or a representation of any current or future portfolio composition. All investing involves risk, including loss of principal.
Biology has become an engineering discipline, and care delivery is becoming a software one. Both curves inflected before the capital structure around them did — and that lag is the opportunity.
Healthcare accounts for roughly 18% of committed private-equity capital, well behind information technology.1 Yet digital health funding rose 19% in 2025 to $22.3B even as deal count fell 9%, with every one of the year's fourteen new unicorns built on AI.2 Capital is concentrating into fewer, later, larger positions.
That concentration rewards conviction and punishes tourism. It also means the marginal dollar increasingly needs a clinical judgement, not just a commercial one — whether the mechanism holds, whether the endpoint means anything, whether the regulator will agree. We underwrite that question first, and the multiple second.
We are guardians of the future against the claims of the present.